Traditionally, ACT has been the standard of care following surgery, but recent advances have highlighted the potential benefits of NACT, particularly in locally advanced, triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2 overexpression (HER2+) patients.2 The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.